This Blend combines two complementary peptides—CJC-1295 No DAC (a modified GHRH fragment) and Ipamorelin (a selective ghrelin receptor agonist)—intended for advanced preclinical research focused on endogenous growth hormone regulation.

CJC-1295 No DAC is a synthetic fragment of Growth Hormone–Releasing Hormone (1–29), engineered to trigger rapid, pulse-like releases of growth hormone due to its short half-life (around 30 minutes). This makes it useful for experiments exploring natural, rhythmic activation of the GH axis.

Ipamorelin is a pentapeptide that acts as a ghrelin receptor (GHSR) agonist, specifically enhancing growth hormone release in research models without influencing cortisol or prolactin levels.

Together, this blend supports synergistic investigation of the GH axis: CJC-1295 No DAC starts GHRH receptor activation in the hypothalamus, while Ipamorelin amplifies growth hormone secretion through the ghrelin pathway. The combination is designed to closely replicate the body’s physiological GH pulse patterns under experimental conditions.